Teva Wins FDA Nod for First Once-Monthly Subcutaneous Olanzapine

Teva Pharmaceutical Industries Ltd. announced on 9 October 2026 that the U.S. Food and Drug Administration approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for schizophrenia in adults. The company said it is the first and only once-monthly subcutaneous olanzapine LAI requiring no loading doses, no oral supplementation and no post-injection monitoring. Teva will ship three strengths — 318 mg, 425 mg and 531 mg — in the coming weeks, and hosts an investor call at 8:00 a.m. ET the same day.

Context — Why an Olanzapine LAI Approval Matters Now

Olanzapine is the most widely prescribed atypical antipsychotic for schizophrenia as a daily oral treatment, Teva said. The company argues daily oral regimens struggle to sustain long-term symptom improvement because of adherence challenges, raising the risk of instability and relapse. WELTRUZA is designed to close that gap by delivering olanzapine's established efficacy through a once-monthly subcutaneous injection.

The approval rests on the pivotal Phase 3 SOLARIS trial. Teva said SOLARIS showed overall symptom improvement, a significant reduction in illness severity and better personal and social functioning, with a systemic safety profile consistent with oral olanzapine. The trial was an eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study covering patients aged 18 to 64, followed by a 48-week second period.

The commercial catalyst is timing. Teva said WELTRUZA will be available in the U.S. in the coming weeks, which puts launch execution in the current quarter rather than a future one. The company also disclosed that the European Medicines Agency accepted its Marketing Authorization Application for olanzapine LAI, referenced as TEV-'749, in May 2026, though that product is not approved by the EMA at this time.

Teva frames the approval inside its Pivot to Growth strategy, saying it continues to deliver on patient-centered innovation in neuroscience and a differentiated long-acting injectable franchise. That framing matters because the company is positioning itself as an innovative biopharmaceutical business enabled by a generics operation, not solely as a generics manufacturer.

Data — What the SOLARIS Numbers and Doses Show

WELTRUZA's three approved strengths map directly onto approved daily oral olanzapine doses: 318 mg corresponds to 10 mg, 425 mg to 15 mg and 531 mg to 20 mg. Teva said all three doses were similarly tolerated in SOLARIS.

The most common adverse events Teva reported were increased weight, somnolence, headache, constipation and injection site reactions. Weight gain and metabolic changes were observed and were consistent with the systemic safety profile of oral olanzapine, including clinically significant weight gain. Discontinuations due to common adverse events were 5% for WELTRUZA versus 4% for placebo, a one-point gap.

SOLARIS measure	WELTRUZA	Placebo
Discontinuation rate from common AEs	5%	4%
Randomised patients, period one	675 total across four arms	675 total across four arms

The trial randomised 675 patients in period one across low, medium and high WELTRUZA doses and placebo in a 1:1:1:1 ratio. In period two, patients who completed on placebo were re-randomised equally to the three active doses, while those already on active treatment stayed at their established strength. Teva said end-of-treatment and follow-up visits came four and eight weeks after the last dose.

On the disease itself, Teva cited an estimated 2.1 million people currently diagnosed with schizophrenia in the U.S., and roughly 1% of the world's population developing the condition in their lifetime. The company said about 80% of patients experience multiple relapses over the first five years of treatment.

Analysis — Where the Value Sits for Teva and Peers

The competitive logic is straightforward. Olanzapine has been a foundational schizophrenia treatment for more than 30 years, as Christoph Correll of the Zucker School of Medicine at Hofstra/Northwell noted in the release. Teva's differentiator is not the molecule but the delivery: a subcutaneous depot that avoids the monitoring burden attached to extended-release intramuscular olanzapine, where post-injection delirium/sedation syndrome has been documented.

The company is careful on that point. It states that PDSS has occurred with another extended-release olanzapine medicine injected intramuscularly, that WELTRUZA is injected subcutaneously, and that it is not known whether PDSS can happen with WELTRUZA. That is an unresolved clinical question, and it is the single largest counter-argument to the monitoring-free claim.

Second-order effects touch Teva's own franchise mix. A subcutaneous LAI with no oral cotreatment and no loading doses competes for the same patients who might otherwise be started on or switched between existing long-acting injectables. Teva said schizophrenia often requires switching from oral options or between LAI options during the treatment journey, which is precisely the switching pool a new entrant targets.

Positioning follows the launch calendar. Investors holding TEVA on the innovative-franchise thesis now have an approved U.S. product with disclosed strengths and a stated near-term availability window, while anyone modelling a slower regulatory path has to re-mark. The offsetting risk is commercial rather than regulatory: payer coverage, injection-site tolerability in real-world use, and clinician adoption of a new subcutaneous technique are all unquantified in the release.

Outlook — What to Watch After the Approval

Three dates and markers matter. First, U.S. availability: Teva said WELTRUZA will be available in the coming weeks, so the launch itself is the next observable event. Second, the investor call on 9 October 2026 at 8:00 a.m. ET, with an archived webcast posted 24 hours after the discussion ends. Third, the EMA review of TEV-'749, whose Marketing Authorization Application was accepted in May 2026 and remains unapproved.

On the pipeline side, Teva said the EMA submission is supported by the same SOLARIS program that underpins the U.S. approval, so the European decision is the next regulatory read on the same data set. The company did not disclose pricing, launch-quarter revenue expectations, or manufacturing capacity for the three strengths.

For the equity, the watch item is whether Teva's Pivot to Growth commentary on the call adds commercial detail beyond the approval itself. Traders should treat any guidance offered there as the company's expectation, not an established outcome.

Frequently Asked Questions

What does the WELTRUZA approval mean for retail investors in TEVA?

It gives Teva an approved U.S. product in its innovative neuroscience franchise, with three disclosed strengths and a stated near-term launch window. What the approval does not supply is pricing, revenue guidance or margin detail, so the financial contribution is unquantified in the announcement. The company's forward-looking statements about commercialisation remain expectations subject to the risks it lists.

What happens next for Teva and the European filing?

The U.S. launch follows in the coming weeks. In Europe, the EMA accepted Teva's Marketing Authorization Application for olanzapine LAI, referred to as TEV-'749, in May 2026, and that product is not approved there. The same Phase 3 SOLARIS study supports the European submission, so the EMA review is the next regulatory milestone on the shared data set.

Why did Teva develop a subcutaneous version instead of another intramuscular LAI?

Teva's stated rationale is adherence. It says daily oral options may make long-term symptom improvement hard to sustain, and that WELTRUZA offers olanzapine's efficacy without loading doses, oral supplementation or post-injection monitoring. The company also notes it is not known whether post-injection delirium/sedation syndrome, documented with an intramuscular extended-release olanzapine, can occur with subcutaneous WELTRUZA.

Bottom Line

Teva now has an FDA-approved, monitoring-free once-monthly subcutaneous olanzapine, shifting the debate from regulatory risk to launch execution.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.